Fundraising FoxThe Column Group — 2026 Investments
3 investments dated 2026 · listed companies and verified rows first · show all
Nura Bio develops neuroprotective medicines targeting neurological diseases by translating scientific advances in axonal degeneration and neuroimmune regulation into novel therapeutics.
BiotechDeep TechDigital HealthHealthtechMedical Devices
Co-investorsSamsara BioCapitalSanofi Ventures
NGM Bio is a biopharmaceutical company developing NGM120, a GDF15/GFRAL antagonist antibody, to treat conditions rooted in overactivation of the GDF15 pathway.
BiotechHealthtechSouth San Francisco, US
Diana Peng Bockus(Executive Officer, Director)
BoardRoger M. Perlmutter(Director)
Board seatPeter SvennilsonTim Kutzkey· per SEC Form D
Co-investorsRho Ventures
The Faculty of Pharmacy and Biochemistry offers pharmacy and biochemistry degree programs, including a Pharmacy programme in English aligned with EU Directive 2005/36/EC for EU/EEA registration.
EdTech
Co-investorsVesna AdvisorsNextech InvestRA Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.